Bruker (NASDAQ:BRKR) Releases FY 2027 Earnings Guidance

Bruker (NASDAQ:BRKR) updated its FY 2027 earnings guidance on Friday. The company provided earnings per share guidance of 4.000-4.300 for the period. The company issued revenue guidance of $4.2 billion-$4.4 billion.

Analyst Upgrades and Downgrades

BRKR has been the topic of several recent research reports. UBS Group boosted their price target on shares of Bruker from $94.00 to $102.00 and gave the company a buy rating in a research report on Friday, March 1st. Stifel Nicolaus increased their price target on Bruker from $63.00 to $81.00 and gave the stock a hold rating in a report on Wednesday, February 14th. Citigroup boosted their price objective on shares of Bruker from $80.00 to $95.00 and gave the company a buy rating in a report on Wednesday, February 14th. The Goldman Sachs Group lifted their price target on shares of Bruker from $66.00 to $74.00 and gave the company a sell rating in a research report on Wednesday, April 10th. Finally, JPMorgan Chase & Co. upgraded shares of Bruker from a neutral rating to an overweight rating and upped their price objective for the stock from $60.00 to $90.00 in a report on Wednesday, February 14th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat.com, Bruker has a consensus rating of Moderate Buy and an average price target of $84.86.

Bruker Trading Down 1.0 %

BRKR opened at $75.07 on Friday. The company has a debt-to-equity ratio of 0.95, a current ratio of 1.81 and a quick ratio of 0.91. The stock has a market capitalization of $10.91 billion, a price-to-earnings ratio of 27.30, a PEG ratio of 1.81 and a beta of 1.22. The business has a fifty day moving average price of $84.74 and a 200 day moving average price of $76.18. Bruker has a 12 month low of $53.79 and a 12 month high of $94.86.

Bruker (NASDAQ:BRKR) last released its earnings results on Thursday, May 2nd. The medical research company reported $0.53 earnings per share for the quarter, topping analysts’ consensus estimates of $0.46 by $0.07. Bruker had a net margin of 13.38% and a return on equity of 27.31%. The firm had revenue of $721.70 million for the quarter, compared to analyst estimates of $729.88 million. During the same period in the prior year, the firm earned $0.64 earnings per share. The business’s quarterly revenue was up 5.3% compared to the same quarter last year. Sell-side analysts expect that Bruker will post 2.82 earnings per share for the current fiscal year.

Bruker Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, June 17th. Shareholders of record on Monday, June 3rd will be issued a dividend of $0.05 per share. This represents a $0.20 dividend on an annualized basis and a yield of 0.27%. The ex-dividend date of this dividend is Friday, May 31st. Bruker’s dividend payout ratio (DPR) is 7.27%.

Insider Activity

In other Bruker news, Director Hermann Fritz Requardt sold 15,000 shares of the company’s stock in a transaction on Monday, March 4th. The shares were sold at an average price of $90.06, for a total value of $1,350,900.00. Following the completion of the transaction, the director now owns 23,147 shares in the company, valued at $2,084,618.82. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 28.30% of the company’s stock.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.